Creative Biolabs news
The controversial subject of fighting cancer is no longer limited to chemotherapy and radiation, and vaccines, once a word tied almost exclusively to infections, are now headline players in oncology. As reported by UCLA Health, a novel cancer vaccine could trigger robust immune responses in patients with pancreatic and colorectal cancer, driving a growing wave of research excitement around cancer vaccines.
Creative Biolabs Shines at the 2024 NIH Research Festival: Showcasing Antibody Solutions
Creative Biolabs made a splash at the 2024 NIH Research Festival, held from Sept. 23–25, as they highlighted their groundbreaking work in antibody discovery and development.
The festival, which featured scientific lectures, poster presentations, and workshops, was a vibrant hub of knowledge exchange, and Creative Biolabs took center stage in presenting their cutting-edge antibody solut
Creative Biolabs, as a top-ranked solution provider of antibody-drug conjugate, scheduled a webinar about improved nuclear localization signal-therapeutics, which went live on January 21, 2022.
Antibody-drug conjugate (ADC) has gained booming attention in the past 2021, with multiple international strategic purchases and breakthrough results of both preclinical and clinical trials. As a forefront of target therapy, it provides the choice of precision medicine for many
Exosomes are picking up steam among scientists because they can perform a role in the immune response, antigen presentation, cell migration, cell differentiation, and tumor invasion. Exosomes, which provide a mechanism for macromolecules to be exchanged between cells, play a part in the development of various illnesses, particularly in the modulation of the cancer microenvironment and immune response.
Recently, several studies have shown that exosomes express some lipids and cell
Scientists now have realized that exosomes, representing a novel mode of intercellular communication, contribute to a wide range of biological processes in health and disease including cancer. Especially, growing evidence shows that tumor-derived exosomes play critical roles in cancer. Exosomes and their cargos may serve as cancer prognostic markers, therapeutic targets or even as anticancer drug-carrier.
As early as around 1800, doctors discovered that certain cancer patients would have their symptoms reduced after being briefly infected with viruses. With the advancement of genetic engineering technology, the idea that viruses have the potential to improve and mediate immunotherapy has been established. Oncolytic viruses (OVs) are such kind of viruses that can replicate in tumor tissues, and kill tumor cells. Up to now, two OV drugs have been marketed globa
Exosomes, small lipid bilayer-enclosed particles of endosomal origin, are a subset of extracellular vesicles (EVs) that are secreted by most cell types. They are spherical, bilayered proteolipids and show a diverse mixture of exosomal nucleic acids (mRNA and non-coding RNA), proteins, and lipids, among which exosomal proteins play a key role in the pathological process of various diseases.
At Creative Biolabs, proteomics technologies have been improved to determine both qualitati
As the incidence and mortality of lung cancer rank among the highest all over the world, lung cancer diagnostics and treatment are the most researched paper topics. Research has reported that exosomes derived from lung cancer are the most promising biomarkers for early diagnosis, prognosis, and treatment of lung cancer. With years of experience in this field, Creative Biolabs provides exosome characterization service and targeted delivery service to advance lung cancer research of global scie
The continuous spread of COVID-19 has become a threat to global health and even has led to a global economic crisis. Researchers arounad the world are putting tremendous effort toward developing vaccines and therapeutic drugs.
Creative Biolabs has been dedicated to the discovery and development of different types of vaccines, including in silico vaccine, live attenuated and killed vaccine, recombinant subunit vaccine, and vaccinia virus vaccine for SARS-C